Impact of withholding breastfeeding around the time of Rotarix vaccination on the immunogenicity of Rotarix vaccine A Randomized Trial
|
|
- Rosalyn Owens
- 5 years ago
- Views:
Transcription
1 Impact of withholding breastfeeding around the time of Rotarix vaccination on the immunogenicity of Rotarix vaccine A Randomized Trial S. Asad Ali, MD, MPH Department of Pediatrics and Child Health Aga Khan University Pakistan 1
2 Why is the immunogenicity of rotavirus vaccines lower in low income settings? 2
3 Why is the immunogenicity of rotavirus vaccines lower in low income settings? Environmental Enteropathy Higher anti-rv antibodies in mother s blood with transplacental transmission Higher anti-rv antibody levels in breast milk Concomitant OPV administration Coexistent intestinal infections 3
4 Why is the immunogenicity of rotavirus vaccines lower in low income settings? Environmental Enteropathy Higher anti-rv antibodies in mother s blood with transplacental transmission Higher anti-rv antibody levels in breast milk Concomitant OPV administration Coexistent intestinal infections 4
5 Moon et al. Page 8 FIGURE 1. Cumulative frequency profiles of rotavirus-specific antibodies in breast milk specimens from mothers in India, Vietnam, Korea and the United States. Milk specimens were tested for IgA (A) and neutralizing activity against vaccine strains Rotarix (B), RotaTeq G1 (C), Moon SS et al. Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines. Pediatr Infect Dis J
6 Why is the immunogenicity of rotavirus vaccines lower in low income settings? Environmental Enteropathy Higher anti-rv antibodies in mother s blood with transplacental transmission Higher anti-rv antibody levels in breast milk Concomitant OPV administration Coexistent intestinal infections 6
7 Primary Objective To compare the immunogenicity of Rotarix in infants whose breastfeeding was withheld one hour before through one hour after vaccination with each Rotarix dose to that in infants who were breastfed at the time of vaccination 7
8 Secondary Objective To determine the effect of rotavirus neutralizing activity in breast milk on the immunogenicity of Rotarix vaccine in infants 8
9
10
11 Trial profile Breas eeding immediately before RV administra on Randomiza on 1: 1 RV/B RV RV/B Breas eeding withheld for one hour before and a er RV administra on RV/B RV RV/B B B (n=200) (n=210) (n=200) (n=210) Birth 6 weeks 10 weeks 14 weeks 18 weeks RV = Rotarix Vaccine B = Blood Draw
12 Randomized (400) Breastfeed Withholding group(200) Immediate Breastfeeding group(200) IgA 20 U/mL (3) Non-compliance with blood draw (1) Lost to follow up/dropout Refusal (9) Illness (1) Moved from Study Area (5) IgA 20 U/mL (6) Non-compliance with blood draw (1) Non-compliance with breastfeeding schedule (5) Lost to follow up/dropout Refusal (9) Death (1) Moved from Study Area (6) Per Protocol (181) Per Protocol (172) 12
13 Baseline Characteristics and Age at visits Withholding Arm (N = 200) Immediate Breastfeed Arm (N = 200) Male 45 % 54 % Age in Weeks 6.3 (0.5) 6.3 (0.5) Weight (g) at 6 weeks (619.2) (594.7) Age of visit in weeks Visit (0.5) 10.4 (0.6) Visit (0.6) 14.6 (0.6) Visit (0.7) 18.7 (0.7) per-protocol population 13
14 Anti-rotavirus IgA antibody seroconversion rates in the per protocol population Age at sample (weeks) 14 (after 2 doses) 18 (after 3 doses) Sero conversion rate Withholding Arm (N=181) 95 % CI Immediate Breastfeed Arm Sero conversion rate (N=172) 95 % CI P-Value 16.6% (11.8; 22.6) 29.1% (22.8; 36.2) % (22.1; 35.1) 37.8% (30.8; 45.2) 0.070
15 Anti-rotavirus IgA antibody seroconversion rates in the per protocol population Age at sample (weeks) 14 (after 2 doses) 18 (after 3 doses) Sero conversion rate Withholding Arm (N=181) 95 % CI Immediate Breastfeed Arm Sero conversion rate (N=172) 95 % CI P-Value 16.6% (11.8; 22.6) 29.1% (22.8; 36.2) % (22.1; 35.1) 37.8% (30.8; 45.2) 0.070
16 Anti-rotavirus IgA antibody seroconversion rates in the per protocol population Age at sample (weeks) 14 (after 2 doses) 18 (after 3 doses) Sero conversion rate Withholding Arm (N=181) 95 % CI Immediate Breastfeed Arm Sero conversion rate (N=172) 95 % CI P-Value 16.6% (11.8; 22.6) 29.1% (22.8; 36.2) % (22.1; 35.1) 37.8% (30.8; 45.2) 0.070
17 Anti-rotavirus IgA geometric mean titers (GMT) for seroconverted subjects after 2 or 3 doses Age at Sample (weeks) Withholding Arm Immediate Breastfeed Arm n GMT 95 % CI n GMT 95 % CI P value 14 (after 2 doses) a (126.2;299.3) (77.3; 140.9) (after 3 doses) b (91.0; 172.9) (69.1; 121.8) a Includes only anti-rotavirus IgA seropositive subjects at 14 weeks b Includes only anti-rotavirus IgA seropositive subjects at 18 weeks 17
18 Anti-rotavirus IgA geometric mean titers (GMT) for seroconverted subjects after 2 or 3 doses Age at Sample (weeks) Withholding Arm Immediate Breastfeed Arm n GMT 95 % CI n GMT 95 % CI P value 14 (after 2 doses) a (126.2;299.3) (77.3; 140.9) (after 3 doses) b (91.0; 172.9) (69.1; 121.8) a Includes only anti-rotavirus IgA seropositive subjects at 14 weeks b Includes only anti-rotavirus IgA seropositive subjects at 18 weeks 18
19 Anti-rotavirus IgA geometric mean titers (GMT) for seroconverted subjects after 2 or 3 doses Age at Sample (weeks) Withholding Arm Immediate Breastfeed Arm n GMT 95 % CI n GMT 95 % CI P value 14 (after 2 doses) a (126.2;299.3) (77.3; 140.9) (after 3 doses) b (91.0; 172.9) (69.1; 121.8) a Includes only anti-rotavirus IgA seropositive subjects at 14 weeks b Includes only anti-rotavirus IgA seropositive subjects at 18 weeks 19
20 Association of Maternally Derived Neutralizing Antibody (MDNA)* titers at 6 weeks with rotavirus seroconversion at 14 weeks (post 2 doses) MDNA at 6 weeks (Percentile) Withholding Arm Immediate Breastfeed Arm Combined (N= 93) (N= 85) (N= 169) Seroconversion rate Seroconversion rate Seroconversion rate < % 38.8% 31.4% > % 22.2% 12.4% P= P= P =0.003 *MDNA measured using 89:12 strain, which is precursor to Rotarix vaccine 20
21 Association of Maternally Derived Neutralizing Antibody (MDNA)* titers at 6 weeks with rotavirus seroconversion at 14 weeks (post 2 doses) MDNA at 6 weeks (Percentile) Withholding Arm Immediate Breastfeed Arm Combined (N= 93) (N= 85) (N= 169) Seroconversion rate Seroconversion rate Seroconversion rate < % 38.8% 31.4% > % 22.2% 12.4% P= P= P =0.003 *MDNA measured using 89:12 strain, which is precursor to Rotarix vaccine 21
22 Association of Maternally Derived Neutralizing Antibody (MDNA)* titers at 6 weeks with rotavirus seroconversion at 14 weeks (post 2 doses) MDNA at 6 weeks (Percentile) Withholding Arm Immediate Breastfeed Arm Combined (N= 93) (N= 85) (N= 169) Seroconversion rate Seroconversion rate Seroconversion rate < % 38.8% 31.4% > % 22.2% 12.4% P= P= P =0.003 *MDNA measured using 89:12 strain, which is precursor to Rotarix vaccine 22
23 Association of Maternally Derived Neutralizing Antibody (MDNA)* titers at 6 weeks with rotavirus seroconversion at 14 or 18 weeks (post 3 doses) MDNA at 6 weeks (Percentile) Withholding Arm Immediate Breastfeed Arm Combined (N= 93) (N= 85) (N= 169) Seroconversion rate Seroconversion rate Seroconversion rate < % 46.9% 42.7% > % 19.5% 14.6% P= P= P < *MDNA measured using 89:12 strain, which is precursor to Rotarix vaccine 23
24 Association of Maternally Derived Neutralizing Antibody (MDNA)* titers at 6 weeks with rotavirus seroconversion at 14 or 18 weeks (post 3 doses) MDNA at 6 weeks (Percentile) Withholding Arm Immediate Breastfeed Arm Combined (N= 93) (N= 85) (N= 169) Seroconversion rate Seroconversion rate Seroconversion rate < % 46.9% 42.7% > % 19.5% 14.6% P= P= P < *MDNA measured using 89:12 strain, which is precursor to Rotarix vaccine 24
25 Association of Maternally Derived Neutralizing Antibody (MDNA)* titers at 6 weeks with rotavirus seroconversion at 14 or 18 weeks (post 3 doses) MDNA at 6 weeks (Percentile) Withholding Arm Immediate Breastfeed Arm Combined (N= 93) (N= 85) (N= 169) Seroconversion rate Seroconversion rate Seroconversion rate < % 46.9% 42.7% > % 19.5% 14.6% P= P= P < *MDNA measured using 89:12 strain, which is precursor to Rotarix vaccine 25
26 Serum Anti-Rotavirus IgA Seroconversion in Immediate Breastfeeding Group, by MDNA and 10-Week BMNA Level Time point Low BMNA in Breast Milk at 10 weeks High BMNA in Breast Milk at 10 weeks (<50 %ile) (>50 %ile) MDNA at 6 weeks Seroconversion rate Seroconversion rate Difference in seroconversion P-value 14 weeks (post 2 doses) <50 %ile 44.4% 20% 24.4% >50 %ile 29% 27.3% 1.8% 1 18 weeks (post 3 doses) <50 %ile 38.9% 38% 0.9% 1 >50 %ile 45.2% 32.7% 12.4% MDNA Maternally derived neutralizing antibodies; BMNA Breast milk neutralizing activity 26
27 Serum Anti-Rotavirus IgA Seroconversion in Immediate Breastfeeding Group, by MDNA and 10-Week BMNA Level Time point Low BMNA in Breast Milk at 10 weeks High BMNA in Breast Milk at 10 weeks (<50 %ile) (>50 %ile) MDNA at 6 weeks Seroconversion rate Seroconversion rate Difference in seroconversion P-value 14 weeks (post 2 doses) <50 %ile 44.4% 20% 24.4% >50 %ile 29% 27.3% 1.8% 1 18 weeks (post 3 doses) <50 %ile 38.9% 38% 0.9% 1 >50 %ile 45.2% 32.7% 12.4% MDNA Maternally derived neutralizing antibodies; BMNA Breast milk neutralizing activity 27
28 Serum Anti-Rotavirus IgA Seroconversion in Immediate Breastfeeding Group, by MDNA and 10-Week BMNA Level Time point Low BMNA in Breast Milk at 10 weeks High BMNA in Breast Milk at 10 weeks (<50 %ile) (>50 %ile) MDNA at 6 weeks Seroconversion rate Seroconversion rate Difference in seroconversion P-value 14 weeks (post 2 doses) <50 %ile 44.4% 20% 24.4% >50 %ile 29% 27.3% 1.8% 1 18 weeks (post 3 doses) <50 %ile 38.9% 38% 0.9% 1 >50 %ile 45.2% 32.7% 12.4% MDNA Maternally derived neutralizing antibodies; BMNA Breast milk neutralizing activity 28
29 Summary of Findings Withholding breast feeding around the time of RV1 vaccine administration did not lead to increased anti-rotavirus IgA seroconversion. To our surprise, IgA seroconversion after two RV1 doses at 6 and 10 weeks was significantly greater in immediately breastfed infants compared with those in whom breast milk was withheld! 29
30 Some nuances! GMT in seropositive infants at 14 weeks was higher in the withholding arm compared to the immediate arm Lower seroconversion in infants in the immediate feeding arm with low MDNA/higher BMNA after two doses suggests that ingesting breast milk with higher BMNA at the same time as vaccine may reduce the immune response in some infants 30
31 Summary Although serum rotavirus IgA is not a perfect correlate of protection, our findings suggest that substantially improved clinical protection is not likely with the strategy of withholding breastfeed around the time of vaccination. We suggest breastfeeding can continue ad lib around the time of RV1 administration. 31
32 But why was serum rotavirus IgA seroconversion higher in the immediate breastfeed group? Chance finding? Additional buffering of gastric acid at the time of vaccine administration? Something immunogenic in breast milk?? 32
33 Aga Khan University Study Team: PATH CDC Asad Ali (PI) Momin Kazi Anita Zaidi Rota study team Jessica Fleming Chris Victor Kathy Neuzil Duncan Steele Margaret Cortese Umesh Parashar Baoming Jia SungSil Moon Patients and their families University of Cincinnati Monica McNeal
Can we improve the performance of live oral rotavirus vaccines?
Can we improve the performance of live oral rotavirus vaccines? Duncan Steele 9 th International Rotavirus Symposium 2 & 3 August 2010, Johannesburg, South Africa Vaccine efficacy against severe rotavirus
More informationBangladesh: How to move from data to implementation. K. Zaman, MBBS, PhD Senior Scientist and Epidemiologist icddr,b
Bangladesh: How to move from data to implementation K. Zaman, MBBS, PhD Senior Scientist and Epidemiologist icddr,b Rotavirus in Bangladesh Estimated 2.4 million cases of rotavirus diarrhoea annually in
More informationInterference of Monovalent, Bivalent, and Trivalent Oral Poliovirus Vaccines on Monovalent Rotavirus Vaccine Immunogenicity in Rural Bangladesh
Clinical Infectious Diseases Advance Access published October 9, 2015 MAJOR ARTICLE Interference of Monovalent, Bivalent, and Trivalent Oral Poliovirus Vaccines on Monovalent Rotavirus Vaccine Immunogenicity
More informationAlternative Rotavirus Vaccine Candidates: Why should we bother?
Alternative Rotavirus Vaccine Candidates: Why should we bother? Duncan Steele Initiative for Vaccine Research, WHO 7 th International Rotavirus Symposium 12-13 June 2006, Lisboa, Portugal Rotavirus Vaccines
More informationRotavirus vaccines: Issues not fully addressed in efficacy trials
Rotavirus vaccines: Issues not fully addressed in efficacy trials TM Umesh D. Parashar Lead, Viral Gastroenteritis Team CDC, Atlanta, USA uparashar@cdc.gov 1 Two New Rotavirus Vaccines Licensed in 2006
More informationWill live oral vaccines work in children in the developing world? Martin Friede Ph.D. Initiative for Vaccine Research
Will live oral vaccines work in children in the developing world? Martin Friede Ph.D. Initiative for Vaccine Research Estimated global distribution of the 600,000 annual deaths caused by rotavirus 2 1
More informationCorrelates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations
Correlates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations Brigitte Cheuvart, Kathleen M. Neuzil, Duncan Steele, Nigel Cunliffe, Shabir A. Madhi,
More informationROTAVIRUS VACCINES. Virology
ROTAVIRUS VACCINES Virology Rotavirus is a triple-layers viral particle belonging to the Reoviridae family. It contains 11 segments of double-stranded RNA, of which 6 are structural and 5 are non-structural
More informationVaccines against Rotavirus & Norovirus. Umesh D. Parashar CDC, Atlanta, GA
TM Vaccines against Rotavirus & Norovirus Umesh D. Parashar CDC, Atlanta, GA 1 Rotavirus is the Leading Cause Of Severe Diarrhea in Children
More informationUpdate on Pentavalent Human-Bovine Rotavirus Vaccine. Michelle Goveia, MD, MPH Medical Director MSD Vaccines India, September 2014
Update on Pentavalent Human-Bovine Rotavirus Vaccine Michelle Goveia, MD, MPH Medical Director MSD Vaccines India, September 2014 Outline Characteristics of RotaTeq and its worldwide use Recent data evaluating
More informationValue of post-licensure data to assess public health value Example of rotavirus vaccines
Value of post-licensure data to assess public health value Example of rotavirus vaccines TM Umesh D. Parashar Lead, Viral Gastroenteritis Team CDC, Atlanta, USA uparashar@cdc.gov 1 Two New Rotavirus Vaccines
More informationSafety and Immunogenicity of a Parenterally Administered Rotavirus VP8 Subunit Vaccine in Healthy Adults
Safety and Immunogenicity of a Parenterally Administered Rotavirus VP8 Subunit Vaccine in Healthy Adults Stanley Cryz 1, Clayton Harro 2, Monica McNeal 3, Nicole Meyer 3, Barbara DeNearing 2, Alicia Cage
More informationNew and Underused Vaccines, Rotavirus
New and Underused Vaccines, Rotavirus George Armah Noguchi Memorial Institute for Medical research University of Ghana 10th Annual African Vaccinology Course (VACFA) Cape town, South Africa 10 th to 14
More informationVaccination with RotaTeq. Questions & Answers for Immunization Providers
Vaccination with RotaTeq Questions & Answers for Immunization Providers Office of the Chief Medical Officer of Health Communicable Disease Control Branch June 2018 1. Why is a rotavirus vaccine program
More informationDevelopment of a heat-stable Rotavirus vaccine using innovative delivery technology
Development of a heat-stable Rotavirus vaccine using innovative delivery technology 1 HILLEMAN OPERATING MODEL IS UNIQUE WITH FOCUS ON TRANSLATIONAL SCIENCE AND GETTING AFFORDABLE VACCINES TO MARKET FASTER
More informationCorrelates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges
Human Vaccines & Immunotherapeutics 10:12, 3659--3671; December 2014; Published with license by Taylor & Francis Group, LLC REVIEW Correlates of protection for rotavirus vaccines: Possible alternative
More informationSeroprotection after Hepatitis B Vaccination among Newborn Infants: a Review
Center for Global Health Seroprotection after Hepatitis B Vaccination among Newborn Infants: a Review Rania Tohme, MD, MPH Team Lead Global Immunization Division, US CDC Viral Hepatitis Prevention Board
More informationRotavirus Vaccines. Gagandeep Kang Christian Medical College Vellore
Rotavirus Vaccines Gagandeep Kang Christian Medical College Vellore Rotavirus disease burden Rotavirus vaccines and candidates Performance of vaccines in developed and developing countries Longitudinal
More informationFecal shedding of rotavirus vaccine in premature babies in the neonatal unit
Fecal shedding of rotavirus vaccine in premature babies in the neonatal unit Dr. Manish Sadarangani Director, Vaccine Evaluation Center, BC Children s Hospital Research Institute Assistant Professor, Division
More informationA Human Rotavirus Vaccine
7th International Rotavirus Symposium Lisbon, Portugal, 12-13 June 2006 A Human Rotavirus Vaccine Dr. Béatrice De Vos GlaxoSmithKline Biologicals Rixensart, Belgium Rotarix is a trade mark of the GlaxoSmithKline
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationNoroviruses. Duncan Steele Bill & Melinda Gates Foundation. Acknowledgements: Ben Lopman and Umesh Parashar, CDC Megan Carey and Julia Bosch, BMGF
Noroviruses Duncan Steele Bill & Melinda Gates Foundation Acknowledgements: Ben Lopman and Umesh Parashar, CDC Megan Carey and Julia Bosch, BMGF 1 Global norovirus burden Globally, norovirus is associated
More informationVaccines including Tdap in pregnancy
Vaccines including Tdap in pregnancy Dr. Manish Sadarangani Director, Vaccine Evaluation Center, BC Children s Hospital Research Institute Assistant Professor, Division of Infectious Diseases, Department
More informationNoninterference of Rotavirus Vaccine With Measles- Rubella Vaccine at 9 Months of Age and Improvements in Antirotavirus Immunity: A Randomized Trial
The Journal of Infectious Diseases MAJOR ARTICLE Noninterference of Rotavirus Vaccine With Measles- Rubella Vaccine at 9 Months of Age and Improvements in Antirotavirus Immunity: A Randomized Trial K.
More informationRoger I. Glass, M.D., Ph.D. Fogarty International Center, NIH Viral Gastroenteritis Unit, CDC
Roger I. Glass, M.D., Ph.D. Fogarty International Center, NIH Viral Gastroenteritis Unit, CDC International Rotavirus Symposia- A 30 year history 1-4. 1984, 1986, 1989, 1991 NIH Bethesda, MD USA 5. 1995
More informationHousehold transmission of rotavirus in Malawian children with acute gastroenteritis is associated with disease severity
Household transmission of rotavirus in Malawian children with acute gastroenteritis is associated with disease severity Dr Aisleen Bennett International Rotavirus Symposium, Minsk, Belarus August 2018
More informationUpdates on Rotasiil development
Updates on Rotasiil development 13 th International Rotavirus Symposium Minsk, Belarus 30 August 2018 Dr Sajjad Desai MD Serum Institute of India Pvt Limited, Pune Rotasiil Bovine-human reassortant strains
More informationRotavirus Vaccines for Infants in Developing Countries in Africa and Asia: Considerations from a World Health Organization Sponsored Consultation
SUPPLEMENT ARTICLE Rotavirus Vaccines for Infants in Developing Countries in Africa and Asia: Considerations from a World Health Organization Sponsored Consultation A. Duncan Steele, 1,2 Manish Patel,
More informationUS Rotavirus Vaccination Program
US Rotavirus Vaccination Program 1 Rotavirus Vaccines in US Feb 2006 Feb 2006 April 2008 June 2008 RotaTeq licensed by FDA RotaTeq recommended by ACIP Rotarix licensed by FDA ACIP to consider Rotarix 2
More informationAssessing the Evidence for Potential Benefits and Risks of Removing the Age Restrictions for Rotavirus Vaccination
Assessing the Evidence for Potential Benefits and Risks of Removing the Age Restrictions for Rotavirus Vaccination Manish Patel SAGE Geneva 12 April 2012 1 Overview! Update new inputs for benefit risk
More informationCytomegalovirus Seroprevalence among Children 1-5 Years of Age in the United States: The National Health and Nutrition Examination Survey,
CVI Accepts, published online ahead of print on 17 December 2014 Clin. Vaccine Immunol. doi:10.1128/cvi.00697-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Cytomegalovirus
More information16 HIV/AIDS Infection and Cell Organelles ALTHOUGH MANY OF their characteristics are similar to those of cells, viruses
16 HIV/AIDS Infection and Cell Organelles ALTHOUGH MANY OF their characteristics are similar to those of cells, viruses are not cells. They contain genetic material and a few proteins, but they do not
More informationCould a combination of OPV & IPV accelerate wild type poliovirus eradication? Nicholas Grassly
Could a combination of OPV & IPV accelerate wild type poliovirus eradication? Nicholas Grassly SAGE working group on IPV (est. Aug 2008) SAGE Members Elizabeth Miller, Chair Hyam Bashour Peter Figueroa
More informationInternational Journal of Biomedicine 5(4) (2015) doi: /Article5(4)_OA1 ORIGINAL ARTICLE. Infection and Immunity
International Journal of Biomedicine 5(4) (2015) 179-183 doi: 10.21103/Article5(4)_OA1 ORIGINAL ARTICLE Infection and Immunity INTERNATIONAL JOURNAL OF BIOMEDICINE Duration of Preservation of Antibodies
More informationDecision-making by the Advisory Committee on Immunization Practices
Decision-making by the Advisory Committee on Immunization Practices Melinda Wharton, MD, MPH Deputy Director, National Center for Immunization & Respiratory Diseases Institute of Medicine 9 February 2012
More informationVaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV
Supplemental Digital Content 1. Methodology Inclusion and exclusion criteria Eligible participants were infants between and including 6 10 weeks of age at the time of the first vaccination, who were free
More informationFeeding the Small for Gestational Age Infant. Feeding the Small for Gestational Age Infant
Feeding the Small for Gestational Age Infant Feeding the Small for Gestational Age Infant What s the right strategy? Infants born small-for-gestational age (SGA) are at higher risk for adult diseases.
More informationGSK Medicine: Rotarix (HRV): GlaxoSmithKline Biologicals live attenuated human rotavirus vaccine Study No.: (EPI-ROTA ) Title:
GSK Medicine: Rotarix (HRV): GlaxoSmithKline Biologicals live attenuated human rotavirus Study No.: 111426 (EPI-ROTA-111426) Title: Case-control study to evaluate the effectiveness of GlaxoSmithKline (GSK)
More informationBreastfeeding and HIV: What We Know and Considerations for Informed Choices
Breastfeeding and HIV: What We Know and Considerations for Informed Choices Thursday, December 13, 2018 Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject
More informationYae-Jean Kim 1, Jong-Hyun Kim 2 Department of Pediatrics, College of Medicine Sungkyunkwan University 1, The Catholic University 2, Republic of Korea
Immunogenicity and safety of a fully liquid DTaP-IPV-HB-PRP~T hexavalent vaccine compared with the standard of care in infants in the Republic of Korea Yae-Jean Kim 1, Jong-Hyun Kim 2 Department of Pediatrics,
More informationGSK Medicine: Study No.: Title: Rationale: Study Period Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationOverview. Alcohol and lactation 9/15/2008
Breastfeeding Alcohol By Roslyn Giglia 15 September 2008 Overview Physiological effect of alcohol on lactation Effect of alcohol on the breastfed infant Some our my research results Focus groups Alcohol
More informationExperience of Pentavalent Human-bovine Reassortant Rotavirus Vaccine Among Healthy Infants in Taiwan
ORIGINAL ARTICLE Experience of Pentavalent Human-bovine Reassortant Rotavirus Vaccine Among Healthy Infants in Taiwan Chien-Chih Chang, 1 Mei-Hwei Chang, 1 * Tzou-Yen Lin, 2 Hong-Chang Lee, 3 Wu-Shiun
More informationMonitoring For Rotavirus Serotypes In The Americas. Jon Gentsch
Monitoring For Rotavirus Serotypes In The Americas Jon Gentsch Centers for Disease Control and Prevention, Atlanta, USA * The findings and conclusions in this presentation are those of the authors and
More informationInfluenza immunization in pregnancy: observations in mother, fetus, infant
Influenza immunization in pregnancy: observations in mother, fetus, infant Mark C. Steinhoff, MD Director, Global Health Center Professor of Pediatrics Cincinnati Children s Hospital Medical Center Cincinnati
More informationWhat s New In Pediatric Vaccines? and Addressing Vaccine Hesitancy
What s New In Pediatric Vaccines? and Addressing Vaccine Hesitancy Kathryn M. Edwards MD Sarah H. Sell and Cornelius Vanderbilt Chair Professor of Pediatrics Vanderbilt University Medical Center Disclosures
More informationConclusions of the SAGE Working Group on Measles and Rubella June 2017, Geneva
Conclusions of the SAGE Working Group on Measles and Rubella 21-22 June 2017, Geneva WHO Policy Recommendation on administration of MCV to infants
More informationI mun u i n s i atio i n o n u p u d p a d te
Immunisation update Brian Eley Paediatric Infectious Diseases Unit Red Cross War Memorial Children s Hospital Department of Paediatrics and Child Health University of Cape Town Immunisation schedules,
More informationDr Michelle Groome MBBCh (Wits) DCH(SA) MScMed (Epi & Biostats) Department of Science and Technology/National Research Foundation: Vaccine
Dr Michelle Groome MBBCh (Wits) DCH(SA) MScMed (Epi & Biostats) Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases; Medical Research Council: Respiratory and
More informationTYPHERIX PRODUCT INFORMATION (Salmonella typhi Vi polysaccharide)
TYPHERIX PRODUCT INFORMATION (Salmonella typhi Vi polysaccharide) DESCRIPTION TYPHERIX is a colourless, sterile liquid containing the cell surface Vi polysaccharide extracted from Salmonella typhi Ty2
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEffectiveness of monovalent rotavirus vaccine in the Philippines 13 th Rotavirus Symposium, 29 Aug 2018, Minsk, Belarus
Effectiveness of monovalent rotavirus vaccine in the Philippines 13 th Rotavirus Symposium, 29 Aug 2018, Minsk, Belarus Anna Lena Lopez, MD, MPH Director, Institute of Child Health and Human Development,
More informationCare of the HIV-Exposed Infant
Care of the HIV-Exposed Infant Use of Flipchart To promote quality and consistency of counseling Why use the counseling flipchart? To improve HIV-exposed infant outcomes through high quality counseling.
More informationKaren L. Kotloff, MD on behalf of the VIDA consortium 13 th International Rotavirus Symposium Minsk, Belarus August 2018
Etiology of diarrheal disease after rotavirus vaccine introduction: The Vaccine Impact on Diarrhea in Africa (VIDA) Study Karen L. Kotloff, MD on behalf of the VIDA consortium 13 th International Rotavirus
More informationRoger I. Glass, M.D., Ph.D. Director, Fogarty International Center Associate Director for International Research, NIH
Rotavirus Vaccines: Prioritization for Introductions- National & International Case Studies Fondation Merieux Conference Center November 27, 2012 Roger I. Glass, M.D., Ph.D. Director, Fogarty International
More informationBreastfeeding comparisons between initiation, days and 6-8 weeks in
Breastfeeding comparisons between initiation, 10-14-days and 6-8 weeks in 2015-16 Breastfeeding comparisons at initiation, 10-14 days and 6-8 weeks in 2015/16 The following report includes information
More informationduring conception, pregnancy and lactation at 2 U.S. medical centers
Use of HIV preexposure prophylaxis during conception, pregnancy and lactation at 2 U.S. medical centers Dominika Seidman, MD Shannon Weber, Maria Teresa Timoney, Karishma Oza, Elizabeth Mullins, Rodney
More informationRotarix TM. Rotavirus vaccine
Rotarix TM Rotavirus vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (1.5 ml) contains: Live attenuated human rotavirus RIX4414 strain* of the G1P[8] type: not less than 10 6.0 CCID 50 *Produced
More informationCUMULATIVE PERINATAL HIV EXPOSURE, AUSTRALIA. Date
CUMULATIVE PERINATAL HIV EXPOSURE, AUSTRALIA 350 300 250 Number 200 150 100 50 0 1/01/1997 1/01/1998 1/01/1999 1/01/2000 31/12/2000 31/12/2001 31/12/2002 Date July 2004 Reported number of perinatally exposed
More informationEvidence of protection against clinical and chronic hepatitis B infection 20 year after infant vaccination in Thailand
Evidence of protection against clinical and chronic hepatitis B infection 20 year after infant vaccination in Thailand http://waipra.blogspot.com/2011/02/9.html Burden of disease in Thailand Liver diseases
More informationGSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/ Centres: Research Methods: Data Source Study Design
GSK Medicine: Rotarix (HRV1): GlaxoSmithKline (GSK) Biologicals oral live attenuated human rotavirus vaccine Study No.: 114910 (EPI-ROTA-025 VE AU DB) Title: A study on the impact of rotavirus vaccination
More informationSUPPLEMENT ARTICLE. of Africa and Asia. The highest rates of rotavirus-associated mortality occur in sub-saharan Africa, where
SUPPLEMENT ARTICLE Comparison of 2 Different Regimens for Reactogenicity, Safety, and Immunogenicity of the Live Attenuated Oral Rotavirus Vaccine RIX4414 Coadministered with Oral Polio Vaccine in South
More informationHexavalent Vaccines: Hepatitis B antibody response and co-administration with other vaccines
Viral Hepatitis Prevention Board Hanoi, 25 26 July 2018 Hexavalent Vaccines: Hepatitis B antibody response and co-administration with other vaccines Prof. Timo Vesikari Vaccine Research Center University
More informationPregnancies amongst adolescents and young women 16% of all births - 19% will have repeat pregnancies before age 20
Introduction Pregnancies amongst adolescents and young women 16% of all births - 19% will have repeat pregnancies before age 20 Proportions HIV infections 19% amongst adolescents (- 29.5% nationally 15
More informationProphylactic HPV Vaccines. Margaret Stanley Department of Pathology Cambridge
Prophylactic HPV Vaccines Margaret Stanley Department of Pathology Cambridge 8kb double stranded DNA viruses, absolutely host and tissue specific, Can t grow virus in tissue culture Classified by genotype
More informationPolio vaccines and polio immunization in the pre-eradication era: WHO position paper. Published in WER 4 June, 2010
Polio vaccines and polio immunization in the pre-eradication era: WHO position paper Published in WER 4 June, 2010 Epidemiology & Background Poliomyelitis (polio) is an acute communicable disease of humans
More informationConclusions and Recommendations of the Experts Meeting on Rotavirus Genotypes in the Region of the Americas
Conclusions and Recommendations of the Experts Meeting on Rotavirus Genotypes in the Region of the Americas Eyal Leshem December 9, 2013 National Center for Immunization & Respiratory Diseases Division
More informationGeneral information on infant feeding
General information on infant feeding for women living with HIV The British HIV Association recommends that the safest way for a mother with HIV to feed her baby is with formula milk, as there is absolutely
More informationSafety of Oral Pentavalent Rotavirus Vaccine in Kenya, Including Among HIV-Infected Infants
Safety of Oral Pentavalent Rotavirus Vaccine in Kenya, Including Among HIV-Infected Infants Geoffrey Nyambane(1), Kayla F. Laserson(1,3), Daniel R. Feikin(1,2), Daveline Nyakundi(1), Earnest Cook(1), Janet
More informationCase study: Evaluation of Rotavirus vaccine impact and safety following introduction into the national immunizations programme of Sudan
15 th ADVAC Case study Rota in Sudan Case study: Evaluation of Rotavirus vaccine impact and safety following introduction into the national immunizations programme of Sudan Background Rotavirus is one
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTOWARDS ELIMINATION OF MOTHER TO CHILD TRANSMISSION OF HIV
TOWARDS ELIMINATION OF MOTHER TO CHILD TRANSMISSION OF HIV Gladwel Muthoni KPA Conference 24 th April, 2018 OUTLINE Burden of HIV in PMTCT Mechanism and timing of Mother to Child Transmission (MTCT) Four
More informationAPPENDIX 4 A4.1 APPENDIX 4
APPENDIX 4 A4.1 APPENDIX 4 APPENDIX 4 A4.3 DEFINITIONS OF THE INDICATORS 1.1 BCG coverage Number 12 23-month-olds receiving BCG vaccine before 1st birthday 1 1.2 DPT coverage Number 12 23-month-olds receiving
More information8 th INTERNATIONAL ROTAVIRUS SYMPOSIUM
PROCEEDINGS FROM THE 8 th INTERNATIONAL ROTAVIRUS SYMPOSIUM June 3 4, 2008 Istanbul, Acknowledgements The Symposium Organizing Committee wishes to thank the following organizations for support of the 8th
More informationRotarix TM. Rotavirus vaccine
Rotarix TM Rotavirus vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution, 1 dose (1 ml) contains: Live attenuated human rotavirus RIX4414 strain not less than 10 6.0 CCID 50 PHARMACEUTICAL
More informationPrevention of MTCT OF HTLV
Prevention of MTCT OF HTLV Sasan.ms May 2018 Determinants of HTLV-1 MTCT Studies on HTLV-1 MTCT determinants have focused mainly on 1. genetic host factors, 2. immunological host factors, 3. lactation
More informationQuestions and Answers for Pediatric Healthcare Providers: Infants and Zika Virus Infection
1 of 5 01/02/2016 20:39 Questions and Answers for Pediatric Healthcare Providers: Infants and Zika Virus Infection Summary CDC has developed interim guidelines for healthcare providers in the United States
More informationThe Childhood Immunization Schedule and the National Immunization Survey
The Childhood Immunization Schedule and the National Immunization Survey Melinda Wharton, MD, MPH Deputy Director, National Center for Immunization & Respiratory Diseases Institute of Medicine 9 February
More informationAll HIV+ Women on Antiretroviral Therapy Should Breastfeed in Both Low and High Resource Settings VOTE NO!!
All HIV+ Women on Antiretroviral Therapy Should Breastfeed in Both Low and High Resource Settings VOTE NO!! Lynne Mofenson MD Elizabeth Glaser Pediatric AIDS Foundation My Esteemed Opponent Will Likely
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPediatric HIV Cure Research
Pediatric HIV Cure Research HIV Cure Research Training Curriculum Pediatric HIV Cure Research Presented by: Priyanka Uprety,MSPH, PhD Laboratory of Deborah Persaud, MD Johns Hopkins University July 2016
More information3. Lymphocyte proliferation (fig. 15.4): Clones of responder cells and memory cells are derived from B cells and T cells.
Chapter 15 Adaptive, Specific Immunity and Immunization* *Lecture notes are to be used as a study guide only and do not represent the comprehensive information you will need to know for the exams. Specific
More informationHaemophilus influenzae type B and Hib Vaccine Chapter 9
Haemophilus influenzae type B and Hib Vaccine Chapter 9 Haemophilus influenzae Aerobic gram-negative bacteria Polysaccharide capsule Six different serotypes (a-f) of polysaccharide capsule 95% of invasive
More informationSummary of Seroprotection after Recombinant Hepatitis B Vaccine Administered to Newborn Infants (defined as the first 30 days of Life) Background:
Prepared by: TV Murphy, MD, September 16, 2016 Summary of Seroprotection after Recombinant Hepatitis B Vaccine Administered to Newborn Infants (defined as the first 30 days of Life) Background: The primary
More informationData and Approaches in National and International Immunization Studies. Emory University, Schools of Public Health & Medicine & CHRSE
Data and Approaches in National and International Immunization Studies Saad B. Omer, MBBS MPH PhD Emory University, Schools of Public Health & Medicine & CHRSE Outline Characteristics of vaccine refusers
More informationRotarix TM. Rotavirus vaccine. 1 dose (1.5 ml) contains: Live attenuated human rotavirus RIX4414 strain
Rotarix TM Rotavirus vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (1.5 ml) contains: Live attenuated human rotavirus RIX4414 strain not less than 10 6.0 CCID50 PHARMACEUTICAL FORM Oral suspension.
More informationVACCINATION. DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M.
VACCINATION DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M. IMMUNIZATION Immunization is defined as the procedure by which the body is prepared to fight against a specific disease. It is used to induce the
More informationLongitudinal Studies of Neutralizing Antibody Responses to Rotavirus in Stools and Sera of Children following Severe Rotavirus Gastroenteritis
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Nov. 1998, p. 897 901 Vol. 5, No. 6 1071-412X/98/$04.00 0 Copyright 1998, American Society for Microbiology. All Rights Reserved. Longitudinal Studies of
More informationManagement of the HIV-Exposed Infant
Management of the HIV-Exposed Infant Katherine Knapp, MD Medical Director, Perinatal Program Department of Infectious Diseases St. Jude Children s Research Hospital Disclosures No conflicts of interest
More informationFor the use only of registered medical practitioners or a hospital or a laboratory ROTARIX. Rotavirus Vaccine (Live Attenuated, Oral) IP
For the use only of registered medical practitioners or a hospital or a laboratory ROTARIX Rotavirus Vaccine (Live Attenuated, Oral) IP 1. NAME OF THE MEDICINAL PRODUCT Rotavirus Vaccine (Live Attenuated,
More informationObjectives. Types of HIV Tests. Age Appropriateness of Tests. Breastfeeding and HIV Testing. Why are there different tests for different ages?
Objectives At the end of the lesson participants will be able to: Identify the types of HIV tests available in Botswana State who should be tested Identify which tests are used for infants and children
More informationNorthwestern Health Unit
Northwestern Health Unit www.nwhu.on.ca 210 First Street North Kenora Ontario P9N 2K4 1-800-830-5978 July 26, 2018 Re: Ontario Rotavirus Immunization Program - Transitioning to RotaTeq (Rot-5) pentavalent
More informationGlaxoSmithKline Biologicals Rotarix WHO PACKAGE INSERT. Rotarix TM 1 WHO Package insert
GlaxoSmithKline Biologicals Rotarix WHO PACKAGE INSERT Rotarix TM 1 WHO Package insert GlaxoSmithKline Biologicals Rotarix Method of administration Rotarix is for oral use only. ROTARIX SHOULD UNDER NO
More informationVIRAL AGENTS CAUSING GASTROENTERITIS
VIRAL AGENTS CAUSING GASTROENTERITIS VIRAL AGENTS CAUSING GASTROENTERITIS Pathogens discussed in our lectures 1. Rotavirus 2. Enteric adenoviruses 3. Caliciviruses 4. Astroviruses 5. Toroviruses Viruses
More informationWhat will happen to these children?
The AIDS Epidemic: An Issue for Maternal and Child Health and Nutrition The AIDS Epidemic: An Issue for Maternal and Child Health and Nutrition Kathleen Rasmussen, PhD Professor, Division of Nutritional
More informationTo demonstrate that DTPa-HBV-IPV/Hib-MenC-TT co-administered with 10Pn, is non-inferior to DTPa-HBV-IPV/Hib coadministered
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationRotarix : Global Efficacy against Severe RV GE due to G1 and non-g1 (G2, G3, G4, G9) RV Types
Rotarix : Global Efficacy against Severe RV GE due to G1 and non-g1 (G2, G3, G4, G9) RV Types 8 th International Rotavirus Symposium Istanbul, 3 rd June 2008 Dr. Norman Begg, Vice President, Clinical Development
More informationIMMUNIZING CHILDREN TO PROTECT AGAINST THE INCREASING RISK OF HEPATITIS A IN ADOLESCENTS AND YOUNG ADULTS IN SOUTH KOREA
IMMUNIZING CHILDREN TO PROTECT AGAINST THE INCREASING RISK OF HEPATITIS A IN ADOLESCENTS AND YOUNG ADULTS IN SOUTH KOREA YM Sohn 1, JS Lee 1, JH Park 1, G Poerschke 2, K Eves 3, J Gress 3 and B Kuter 3
More information